Literature DB >> 15694511

Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro.

Garry L Morefield1, Anna Sokolovska, Dongping Jiang, Harm HogenEsch, J Paul Robinson, Stanley L Hem.   

Abstract

An important step in the induction of an immune response to vaccines is the internalization of antigens by antigen presenting cells, such as dendritic cells (DCs). Many current vaccines are formulated with antigens adsorbed to an aluminum-containing adjuvant. Following injection of the vaccine the antigens may either elute or stay adsorbed to the adjuvant surface. Antigens, which elute from the adjuvant surface, are internalized by dendritic cells through macropinocytosis while those that remain adsorbed are internalized with the adjuvant particle by phagocytosis. The relative efficiency of these two routes of internalization was studied. Alpha casein (AC) labeled with a green fluorescent dye was selected as the model antigen. In order to model vaccine antigens that elute from aluminum-containing adjuvants following administration, dendritic cells were incubated with a solution of fluorochrome-labeled alpha casein. To model vaccine antigens that do not elute from aluminum-containing adjuvants following administration, dendritic cells were exposed to fluorochrome-labeled alpha casein adsorbed to aluminum hydroxide adjuvant (AH). Alpha casein has eight phosphate groups and adsorbs to aluminum hydroxide adjuvant through ligand exchange. Alpha casein does not elute from aluminum hydroxide adjuvant upon exposure to cell culture media. The uptake of antigen by dendritic cells was determined at 0.5, 1, 2 and 3h by confocal microscopy and flow cytometry. Dendritic cells internalized both alpha casein in solution and alpha casein adsorbed to aluminum hydroxide adjuvant. However, the mean fluorescence intensity of dendritic cells incubated with adsorbed alpha casein was four times greater than dendritic cells incubated with alpha casein in solution. In addition, the internalization of alpha casein was enhanced when the mean aggregate diameter of the adjuvant in the cell culture media was reduced from 17 microm to 3 microm. It was concluded that antigen internalization by dendritic cells was enhanced when the antigen remained adsorbed to the aluminum-containing adjuvant following administration and the aggregate size of the adjuvant was smaller than dendritic cells which are approximately 10 microm in diameter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694511     DOI: 10.1016/j.vaccine.2004.07.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  70 in total

Review 1.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  Formulation of vaccines containing CpG oligonucleotides and alum.

Authors:  Joan A Aebig; Gregory E D Mullen; Gelu Dobrescu; Kelly Rausch; Lynn Lambert; Olubunmi Ajose-Popoola; Carole A Long; Allan Saul; Aaron P Miles
Journal:  J Immunol Methods       Date:  2007-05-11       Impact factor: 2.303

Review 3.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

4.  Alum's adjuvant action: grease is the word.

Authors:  M Lamine Mbow; Ennio De Gregorio; Jeffrey B Ulmer
Journal:  Nat Med       Date:  2011-04       Impact factor: 53.440

Review 5.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

6.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

Review 7.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

8.  Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Authors:  Kimberly J Hassett; Megan C Cousins; Lilia A Rabia; Chrystal M Chadwick; Joanne M O'Hara; Pradyot Nandi; Robert N Brey; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2013-04-10       Impact factor: 5.571

9.  Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.

Authors:  Thorsten Demberg; Egidio Brocca-Cofano; Seraphin Kuate; Stanley Aladi; Diego A Vargas-Inchaustegui; David Venzon; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; Janet DiPasquale; Ruth M Ruprecht; David C Montefiori; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

Review 10.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.